Ebastine in combination with docetaxel or cabazitaxel as a treatment for metastatic castration-resistant prostate cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518035-11-01

Enrollment

Registered

2024-12-09

Start date

2024-06-02

Completion date

Unknown

Last updated

2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic castration-resistant prostate cancer (mCRPC)

Brief summary

Change in blood and urine Bis(monoacylglycero)phosphate (BMP)

Detailed description

• PSA response rate (≥ 50% decline in PSA compared to baseline according to PCWG3.) • Radiologic progression free survival (rPFS). • Time to PSA progression defined in accordance with PCWG3. • Toxicity in the combination of docetaxel and ebastine.

Interventions

DRUGTAXOTERE 20 mg/1 ml concentrate for solution for infusion

DRUGEbastin Orifarm 20 mg filmdragerade tabletter

DRUGJEVTANA 60 mg concentrate and solvent for solution for infusion.

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in blood and urine Bis(monoacylglycero)phosphate (BMP)	—

Secondary

Measure	Time frame
• PSA response rate (≥ 50% decline in PSA compared to baseline according to PCWG3.) • Radiologic progression free survival (rPFS). • Time to PSA progression defined in accordance with PCWG3. • Toxicity in the combination of docetaxel and ebastine.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026